We are supported by
We are advancing a lead programme in second-line and later metastatic colorectal cancer, with a tumour-agnostic engine designed to extend the same platform to further solid tumours over time. We are also working on tumour-specific assets for harder-to-treat cases, and an in-vivo programme to enable public-healthcare access where autologous therapy cost may be prohibitive.
All programmes are pre-clinical. Stage labels describe current focus and planned sequence; they are not claims of clinical progress or timing.
Programme identifiers are illustrative placeholders. Stage positions reflect current research focus, not regulatory milestones.
The lead programme proves the platform on a defined indication. Because the navigation engine is designed to be tumour-agnostic, the same systems are intended to extend to further solid tumours — sequenced by evidence, not ambition.
mCRC 2L+ — the proving ground for the full integrated construct.
Candidates where the same recognition and navigation logic is expected to apply.
The STNAV and Stayble-T engine carried across programmes rather than rebuilt each time.
Each expansion step advances only when its readout bar is cleared.
We are supported by